FY2024 EPS Estimates for Inozyme Pharma Raised by Analyst

Inozyme Pharma, Inc. (NASDAQ:INZY) – Research analysts at HC Wainwright increased their FY2024 EPS estimates for Inozyme Pharma in a report issued on Wednesday, November 6th. HC Wainwright analyst E. White now anticipates that the company will earn ($1.62) per share for the year, up from their prior estimate of ($1.77). HC Wainwright currently has a “Buy” rating and a $14.00 target price on the stock. The consensus estimate for Inozyme Pharma’s current full-year earnings is ($1.68) per share. HC Wainwright also issued estimates for Inozyme Pharma’s Q4 2024 earnings at ($0.42) EPS, FY2025 earnings at ($1.74) EPS and FY2026 earnings at ($1.89) EPS.

Inozyme Pharma (NASDAQ:INZY) last posted its earnings results on Tuesday, November 5th. The company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.05.

A number of other brokerages have also issued reports on INZY. Needham & Company LLC reiterated a “buy” rating and issued a $23.00 price objective on shares of Inozyme Pharma in a report on Wednesday. Wedbush reissued an “outperform” rating and set a $12.00 target price (down previously from $15.00) on shares of Inozyme Pharma in a research report on Tuesday. Jefferies Financial Group reissued a “buy” rating and set a $17.00 target price (up previously from $16.00) on shares of Inozyme Pharma in a research report on Tuesday, August 13th. Finally, Stifel Nicolaus began coverage on shares of Inozyme Pharma in a research report on Thursday, September 12th. They set a “buy” rating and a $16.00 target price for the company. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, Inozyme Pharma presently has a consensus rating of “Buy” and an average price target of $15.71.

Inozyme Pharma Stock Down 3.1 %

Shares of NASDAQ INZY opened at $4.10 on Friday. The company has a 50 day simple moving average of $5.13 and a 200 day simple moving average of $4.92. The firm has a market cap of $257.19 million, a PE ratio of -2.81 and a beta of 1.54. Inozyme Pharma has a 1 year low of $2.71 and a 1 year high of $7.80. The company has a debt-to-equity ratio of 0.48, a current ratio of 9.84 and a quick ratio of 9.84.

Institutional Investors Weigh In On Inozyme Pharma

A number of hedge funds have recently made changes to their positions in the business. Values First Advisors Inc. purchased a new stake in Inozyme Pharma in the 2nd quarter worth about $76,000. Samlyn Capital LLC grew its holdings in Inozyme Pharma by 15.0% during the 2nd quarter. Samlyn Capital LLC now owns 3,350,535 shares of the company’s stock valued at $14,943,000 after buying an additional 437,622 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in Inozyme Pharma by 14.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 21,427 shares of the company’s stock valued at $96,000 after buying an additional 2,690 shares in the last quarter. Affinity Asset Advisors LLC grew its holdings in shares of Inozyme Pharma by 8.1% during the second quarter. Affinity Asset Advisors LLC now owns 2,856,252 shares of the company’s stock worth $12,739,000 after purchasing an additional 213,733 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Inozyme Pharma by 117.6% during the second quarter. Dimensional Fund Advisors LP now owns 380,064 shares of the company’s stock worth $1,695,000 after purchasing an additional 205,417 shares in the last quarter. 88.30% of the stock is currently owned by institutional investors.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.